Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 14, 2026
Reporting period
Not applicable
Filed with the SEC
Jul 28, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001213900-26-082273
Filed / recorded
Jul 28, 2026, 8:15 PM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Unicycive Therapeutics, Inc.
Issuer CIK
1766140
Ticker
UNCY
Reporting person
Sara Kenkare-mitra
Relationship
Director
Security
Restricted Stock Units
Table
Derivative (Table II)
Transaction date
May 14, 2026
Transaction code
A
Shares / units
47,941
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
47,941
Ownership form
Direct
Amendment
Yes (Form 4/A)
Footnotes from the filing
Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.